back to news

Examining Inflammatory Cytokines In Serum And Plasma

GENETIC ENGINEERING & BIOTECHNOLOGY NEWS

By Dandan Shan, Ph.D., David Wilson, Ph.D. 

The future of immuno-oncology treatment and autoimmune diagnostics will involve the detection and quantification of inflammatory biomarkers. As immunotherapy becomes a more common approach for treating cancer and inflammatory disease, cytokines will not only play a role in determining a patient’s disease diagnosis, prognosis, and potential treatment options, but also may serve as a primary index of a therapy’s effectiveness.

Incorporating these biomarkers into clinical practice, however, has been a challenge. Only a few cytokines have been studied in relation to inflammatory disease and immunotherapy, mainly because the biomarkers for these conditions are typically present in very small concentrations, and current research methods aren’t sensitive enough to detect them. It is critical that physicians have the ability to quantify these cytokines to track disease progression before and after treatment.

This tutorial explains how to use the Human Cytokine 6-Plex Panel 1 with the new benchtop Quanterix SR-Plex™ Ultra-Sensitive Biomarker Detection System to simultaneously detect and quantify six inflammatory biomarkers with unprecedented sensitivity using an ELISA-based method. This advanced approach reduces assay volume requirements for multiple sample types and may be sensitive enough to detect circulating disease biomarkers before symptoms appear. As a result, it could potentially provide physicians with a new capability to track disease progression, and the effectiveness of treatments against diseases, which they previously could not monitor with such precision.

Read the rest of the tutorial at genengnews.com